| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NES1 |
| Uniprot No | O43240 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-274aa |
| 氨基酸序列 | AEAALLPQNDTRLDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLGPRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIR |
| 预测分子量 | 30.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NES1重组蛋白的3篇参考文献示例(注：文献信息为虚构，仅供示例参考)：
1. **文献名称**: *Expression and Functional Analysis of Recombinant NES1 in Breast Cancer Cells*
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌系统成功表达重组NES1蛋白，发现其能诱导乳腺癌细胞凋亡并抑制侵袭，提示其作为肿瘤治疗靶点的潜力。
2. **文献名称**: *NES1 Recombinant Protein Suppresses Ovarian Tumor Growth via Protease-Activated Receptor Signaling*
**作者**: Chen L, et al.
**摘要**: 利用哺乳动物细胞表达体系纯化NES1重组蛋白，证实其通过激活PAR2信号通路抑制卵巢癌细胞增殖，并在小鼠模型中减少肿瘤体积。
3. **文献名称**: *Biochemical Characterization of NES1/KLK10 Serine Protease Activity*
**作者**: Gupta R, et al.
**摘要**: 通过昆虫细胞系统获得高活性NES1重组蛋白，分析其底物特异性及酶动力学参数，揭示其在细胞外基质降解中的潜在作用。
(注：以上文献为模拟内容，实际研究中请通过PubMed、Web of Science等平台检索具体文献。)
**Background of NES1 Recombinant Protein**
NES1 (Neuroendocrine Secretory Protein 1), also known as kallikrein 10 (KLK10), is a serine protease encoded by the *KLK10* gene, part of the human kallikrein gene family located on chromosome 19q13.4. Initially identified in 1996. NES1 is expressed in various tissues, including endocrine, reproductive, and epithelial systems. It gained attention due to its potential role as a tumor suppressor, particularly in hormone-related cancers like breast, ovarian, and prostate cancers, where its expression is often downregulated.
Structurally, NES1 is synthesized as a pre-proenzyme containing a signal peptide, pro-peptide, and catalytic domain. It requires proteolytic activation to exhibit enzymatic activity, primarily cleaving substrates such as fibronectin and insulin-like growth factor-binding proteins. Beyond its proteolytic function, NES1 participates in cellular processes like apoptosis, differentiation, and inflammation, mediated through interactions with extracellular matrix components or signaling pathways like the TGF-β and Wnt cascades.
Recombinant NES1 is produced using expression systems (e.g., *E. coli*, mammalian cells) to study its biochemical properties and therapeutic potential. Its tumor-suppressive effects, including inhibition of cancer cell proliferation and metastasis, have spurred interest in developing NES1-based diagnostics or therapies. Additionally, circulating NES1 levels are explored as biomarkers for cancer prognosis. Challenges remain in understanding its precise mechanisms, regulation, and clinical applicability, but ongoing research highlights its significance in oncology and molecular medicine.
In summary, NES1 recombinant protein serves as a critical tool for unraveling the biological and pathological roles of this protease, bridging gaps between basic research and translational applications.
×
